Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting
Tempus AI (NASDAQ: TEM) announced its first-time presentation of 4 research abstracts at the American College of Cardiology (ACC) Annual Meeting from March 29-31 in Chicago. The abstracts showcase the company's AI applications in cardiovascular care.
The research includes: (1) Machine learning models for predicting left ventricular systolic dysfunction, (2) EHR-integrated notifications for sudden cardiac arrest risk assessment, (3) Study on racial disparities in valvular heart disease from April 2019 to January 2024, and (4) Natural language processing application in cardiac transthyretin amyloidosis diagnosis.
According to Dr. Brandon Fornwalt, SVP of Cardiology at Tempus, the company aims to enable clinicians to provide improved, guideline-recommended care for patients with undiagnosed or undertreated cardiovascular disease through their AI-enabled insights and provider network.
Tempus AI (NASDAQ: TEM) ha annunciato la sua prima presentazione di 4 abstract di ricerca al Meeting Annuale dell'American College of Cardiology (ACC) che si svolgerà dal 29 al 31 marzo a Chicago. Gli abstract evidenziano le applicazioni dell'IA dell'azienda nella cura cardiovascolare.
La ricerca include: (1) modelli di apprendimento automatico per prevedere la disfunzione sistolica ventricolare sinistra, (2) notifiche integrate nella cartella clinica elettronica per la valutazione del rischio di arresto cardiaco improvviso, (3) studio sulle disparità razziali nelle malattie valvolari cardiache dal aprile 2019 a gennaio 2024, e (4) applicazione del processamento del linguaggio naturale nella diagnosi dell'amiloidosi cardiaca da transtiretina.
Secondo il Dr. Brandon Fornwalt, SVP di Cardiologia presso Tempus, l'azienda mira a consentire ai medici di fornire cure migliorate, raccomandate dalle linee guida, per i pazienti con malattie cardiovascolari non diagnosticate o trattate inadeguatamente attraverso le loro intuizioni abilitate dall'IA e la rete di fornitori.
Tempus AI (NASDAQ: TEM) anunció su primera presentación de 4 resúmenes de investigación en el Congreso Anual del American College of Cardiology (ACC) que se llevará a cabo del 29 al 31 de marzo en Chicago. Los resúmenes destacan las aplicaciones de IA de la empresa en el cuidado cardiovascular.
La investigación incluye: (1) modelos de aprendizaje automático para predecir la disfunción sistólica del ventrículo izquierdo, (2) notificaciones integradas en la historia clínica electrónica para la evaluación del riesgo de paro cardíaco súbito, (3) estudio sobre las disparidades raciales en la enfermedad valvular cardíaca desde abril de 2019 hasta enero de 2024, y (4) aplicación de procesamiento de lenguaje natural en el diagnóstico de amiloidosis cardíaca por transtiretina.
Según el Dr. Brandon Fornwalt, SVP de Cardiología en Tempus, la empresa tiene como objetivo permitir a los clínicos proporcionar una atención mejorada, recomendada por las guías, para pacientes con enfermedades cardiovasculares no diagnosticadas o tratadas de manera inadecuada a través de sus conocimientos habilitados por IA y su red de proveedores.
템퍼스 AI (NASDAQ: TEM)는 3월 29일부터 31일까지 시카고에서 열리는 미국 심장학회(ACC) 연례 회의에서 4개의 연구 초록을 처음으로 발표한다고 발표했습니다. 이 초록들은 회사의 심혈관 치료에 대한 AI 응용 프로그램을 보여줍니다.
연구 내용은 다음과 같습니다: (1) 좌심실 수축 기능 부전을 예측하기 위한 기계 학습 모델, (2) 갑작스러운 심정지 위험 평가를 위한 전자 건강 기록 통합 알림, (3) 2019년 4월부터 2024년 1월까지의 심장 판막 질환에 대한 인종적 불평등 연구, (4) 심장 트랜스티레틴 아밀로이드증 진단에 대한 자연어 처리 응용 프로그램.
템퍼스의 심장학 부사장인 브랜든 포른왈트 박사에 따르면, 이 회사는 AI 기반 통찰력과 제공자 네트워크를 통해 진단되지 않거나 적절히 치료되지 않은 심혈관 질환 환자에게 개선된 가이드라인 권장 치료를 제공할 수 있도록 임상의들에게 도움을 주는 것을 목표로 하고 있습니다.
Tempus AI (NASDAQ: TEM) a annoncé sa première présentation de 4 résumés de recherche lors de la Réunion Annuelle de l'American College of Cardiology (ACC) qui se tiendra du 29 au 31 mars à Chicago. Les résumés mettent en avant les applications de l'IA de l'entreprise dans les soins cardiovasculaires.
La recherche comprend : (1) des modèles d'apprentissage automatique pour prédire la dysfonction systolique du ventricule gauche, (2) des notifications intégrées dans le dossier de santé électronique pour l'évaluation du risque d'arrêt cardiaque soudain, (3) une étude sur les disparités raciales dans les maladies valvulaires cardiaques d'avril 2019 à janvier 2024, et (4) une application de traitement du langage naturel dans le diagnostic de l'amyloïdose cardiaque à transthyrétine.
Selon le Dr. Brandon Fornwalt, SVP de Cardiologie chez Tempus, l'entreprise vise à permettre aux cliniciens de fournir des soins améliorés, recommandés par les directives, aux patients atteints de maladies cardiovasculaires non diagnostiquées ou mal traitées grâce à leurs insights habilités par l'IA et leur réseau de fournisseurs.
Tempus AI (NASDAQ: TEM) hat seine erste Präsentation von 4 Forschungsabstracts auf dem Jahrestreffen des American College of Cardiology (ACC) angekündigt, das vom 29. bis 31. März in Chicago stattfindet. Die Abstracts zeigen die KI-Anwendungen des Unternehmens in der kardiovaskulären Versorgung.
Die Forschung umfasst: (1) Maschinelles Lernen-Modelle zur Vorhersage der linksventrikulären systolischen Dysfunktion, (2) EHR-integrierte Benachrichtigungen zur Risikobewertung eines plötzlichen Herzstillstands, (3) Studie zu rassischen Ungleichheiten bei Herzklappenerkrankungen von April 2019 bis Januar 2024 und (4) Anwendung der natürlichen Sprachverarbeitung bei der Diagnose der kardialen Transthyretin-Amyloidose.
Laut Dr. Brandon Fornwalt, SVP der Kardiologie bei Tempus, zielt das Unternehmen darauf ab, Klinikern zu ermöglichen, verbesserte, richtliniengerechte Behandlungen für Patienten mit nicht diagnostizierten oder unzureichend behandelten kardiovaskulären Erkrankungen durch ihre KI-gestützten Erkenntnisse und das Anbieter-Netzwerk bereitzustellen.
- First-time presentation of AI research at major cardiac conference demonstrates expansion into cardiovascular medicine
- Development of AI-powered diagnostic tools for multiple cardiac conditions shows technological advancement
- Large-scale implementation of EHR-integrated notification system indicates practical application of technology
- None.
“Tempus is committed to enabling clinicians to provide better, guideline-recommended care to patients who may have undiagnosed or undertreated cardiovascular disease,” said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. “Through our vast connected network of providers and ability to deliver AI-enabled insights at scale, we can help clinicians close care gaps for patients in a way that wasn’t possible before.”
Highlights from Tempus’ abstracts include:
-
Abstract 184: Development of machine learning models incorporating clinical, demographic, and echocardiography variables for predicting left ventricular systolic dysfunction in patients with isolated left ventricular dilation
- Session Date & Time: Saturday, March 29, 9:30 AM CDT
-
Overview: The goal of this study is to create predictive models for the development of left ventricular (LV) systolic dysfunction in patients with isolated LV dilation (ILVD). This preliminary work identifies predictors and demonstrates the ability to predict progression in patients with ILVD.
-
Abstract 140: Implementation of EHR-integrated notifications on patients at risk for sudden cardiac arrest
- Session Date & Time: Saturday, March 29, 11:00 AM CDT
-
Overview: This study looks at the implementation of electronic health record (EHR) integrated notifications to identify patients at risk for sudden cardiac arrest (SCA) who may benefit from Implantable Cardioverter Defibrillators (ICD). The conclusion is EHR-integrated notifications can help close care gaps for undermanaged patients at risk for SCA.
-
Abstract 127: Addressing racial disparities in valvular heart disease: the role of echo-driven EHR alerts in improving care access
- Session Date & Time: Saturday, March 29, 11:00 AM CDT
-
Overview: The focus of this study is on addressing racial disparities in valvular heart disease, specifically severe aortic stenosis (SAS) and severe mitral regurgitation (SMR). The study observed race-based trends in access to appropriate care for patients at a tertiary care center from April 2019 to January 2024.
-
Abstract 174: Enhancing diagnostic accuracy and treatment appropriateness in cardiac transthyretin amyloidosis through natural language processing: a retrospective analysis
- Session Date & Time: Sunday, March 30, 9:00 AM CDT
- Overview: This study looked at the challenges of diagnosing cardiac transthyretin amyloidosis (cardiac ATTR) and how natural language processing (NLP) can help. The study concludes that significant care gaps exist in managing cardiac ATTR and that integrating NLP into clinical workflows can improve diagnostic accuracy and help patients access therapies.
To learn more, visit www.tempus.co/acc-2025.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of these abstracts; the contributions of these abstracts to the larger scientific community, and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; including our ability to realize the expected benefits of the acquisition of Ambry Genetics; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250329800085/en/
Hanah Heintzelman
media@tempus.com
Source: Tempus AI, Inc.